Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.51 |
| ▸ | WNT3A | P56704 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979734 | 0.81 | CTNNB1 (0.71) | CAPN1CTNNB1WNT3ANPC1HDAC8 | |
| SCHEMBL7061701 | 0.80 | ABCB1 (0.50) | NPC1HPGDALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL20023080 | 0.78 | NPC1 (0.65) | NPC1ALDH1A1KMT2AL3MBTL1RAB9A | |
| SCHEMBL6203601 | 0.78 | ABCB1 (0.62) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL8432905 | 0.78 | ALDH1A1 (0.65) | NPC1TP53GLAHPGDALDH1A1 | |
| SCHEMBL20023074 | 0.78 | ACHE (0.51) | CTNNB1WNT3ANPC1HDAC8HDAC1 | |
| SCHEMBL30609633 | 0.78 | CTNNB1 (0.63) | CAPN1CTNNB1WNT3ANPC1HDAC8 | |
| SCHEMBL5081630 | 0.78 | CTNNB1 (0.63) | CAPN1CTNNB1WNT3ANPC1HDAC8 | |
| SCHEMBL23805175 | 0.77 | ALDH1A1 (0.56) | NPC1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL15979736 | 0.76 | NPC1 (0.76) | CTNNB1WNT3ANPC1HDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | CAPN1 1024/4885CTNNB1 4562/4885WNT3A 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.